vs
亚什兰（ASH）与CORCEPT THERAPEUTICS INC（CORT）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是CORCEPT THERAPEUTICS INC的1.9倍（$386.0M vs $202.1M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs -3.1%，领先15.1%），CORCEPT THERAPEUTICS INC同比增速更快（11.1% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $38.4M），过去两年CORCEPT THERAPEUTICS INC的营收复合增速更高（17.3% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
ASH vs CORT — 直观对比
营收规模更大
ASH
是对方的1.9倍
$202.1M
营收增速更快
CORT
高出15.8%
-4.7%
净利率更高
CORT
高出15.1%
-3.1%
自由现金流更多
ASH
多$72.6M
$38.4M
两年增速更快
CORT
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $202.1M |
| 净利润 | $-12.0M | $24.3M |
| 毛利率 | 27.2% | 98.7% |
| 营业利润率 | -1.6% | 2.2% |
| 净利率 | -3.1% | 12.0% |
| 营收同比 | -4.7% | 11.1% |
| 净利润同比 | 92.7% | -21.0% |
| 每股收益（稀释后） | $-0.26 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHCORT
| Q4 25 | $386.0M | $202.1M | ||
| Q3 25 | $477.0M | $207.6M | ||
| Q2 25 | $463.0M | $194.4M | ||
| Q1 25 | $479.0M | $157.2M | ||
| Q4 24 | $405.0M | $181.9M | ||
| Q3 24 | $521.0M | $182.5M | ||
| Q2 24 | $544.0M | $163.8M | ||
| Q1 24 | $575.0M | $146.8M |
净利润ASHCORT
| Q4 25 | $-12.0M | $24.3M | ||
| Q3 25 | $31.0M | $19.7M | ||
| Q2 25 | $-742.0M | $35.1M | ||
| Q1 25 | $31.0M | $20.5M | ||
| Q4 24 | $-165.0M | $30.7M | ||
| Q3 24 | $17.0M | $47.2M | ||
| Q2 24 | $6.0M | $35.5M | ||
| Q1 24 | $120.0M | $27.8M |
毛利率ASHCORT
| Q4 25 | 27.2% | 98.7% | ||
| Q3 25 | 33.3% | 97.8% | ||
| Q2 25 | 28.5% | 98.2% | ||
| Q1 25 | 30.7% | 98.5% | ||
| Q4 24 | 27.4% | 98.4% | ||
| Q3 24 | 33.2% | 98.4% | ||
| Q2 24 | 34.2% | 98.5% | ||
| Q1 24 | 28.0% | 98.3% |
营业利润率ASHCORT
| Q4 25 | -1.6% | 2.2% | ||
| Q3 25 | 12.8% | 4.9% | ||
| Q2 25 | -152.9% | 13.7% | ||
| Q1 25 | 10.6% | 2.2% | ||
| Q4 24 | -44.2% | 13.9% | ||
| Q3 24 | 6.1% | 25.5% | ||
| Q2 24 | -11.2% | 21.7% | ||
| Q1 24 | 3.7% | 20.1% |
净利率ASHCORT
| Q4 25 | -3.1% | 12.0% | ||
| Q3 25 | 6.5% | 9.5% | ||
| Q2 25 | -160.3% | 18.1% | ||
| Q1 25 | 6.5% | 13.1% | ||
| Q4 24 | -40.7% | 16.9% | ||
| Q3 24 | 3.3% | 25.9% | ||
| Q2 24 | 1.1% | 21.7% | ||
| Q1 24 | 20.9% | 18.9% |
每股收益（稀释后）ASHCORT
| Q4 25 | $-0.26 | $0.20 | ||
| Q3 25 | $0.83 | $0.16 | ||
| Q2 25 | $-16.21 | $0.29 | ||
| Q1 25 | $0.65 | $0.17 | ||
| Q4 24 | $-3.50 | $0.25 | ||
| Q3 24 | $0.34 | $0.41 | ||
| Q2 24 | $0.12 | $0.32 | ||
| Q1 24 | $2.39 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $372.2M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $647.8M |
| 总资产 | $4.5B | $836.7M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHCORT
| Q4 25 | $304.0M | $372.2M | ||
| Q3 25 | $215.0M | $421.7M | ||
| Q2 25 | $207.0M | $342.2M | ||
| Q1 25 | $168.0M | $322.8M | ||
| Q4 24 | $219.0M | $383.3M | ||
| Q3 24 | $300.0M | $380.3M | ||
| Q2 24 | $399.0M | $473.2M | ||
| Q1 24 | $439.0M | $410.8M |
总债务ASHCORT
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ASHCORT
| Q4 25 | $1.9B | $647.8M | ||
| Q3 25 | $1.9B | $631.9M | ||
| Q2 25 | $1.9B | $635.8M | ||
| Q1 25 | $2.6B | $683.3M | ||
| Q4 24 | $2.6B | $679.6M | ||
| Q3 24 | $2.9B | $638.8M | ||
| Q2 24 | $3.0B | $596.2M | ||
| Q1 24 | $3.1B | $547.9M |
总资产ASHCORT
| Q4 25 | $4.5B | $836.7M | ||
| Q3 25 | $4.6B | $823.6M | ||
| Q2 25 | $4.6B | $801.7M | ||
| Q1 25 | $5.2B | $846.5M | ||
| Q4 24 | $5.2B | $840.6M | ||
| Q3 24 | $5.6B | $784.3M | ||
| Q2 24 | $5.7B | $714.6M | ||
| Q1 24 | $5.9B | $655.9M |
负债/权益比ASHCORT
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $38.4M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $38.4M |
| 自由现金流率自由现金流/营收 | 28.8% | 19.0% |
| 资本支出强度资本支出/营收 | 3.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.58× |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHCORT
| Q4 25 | $125.0M | $38.4M | ||
| Q3 25 | $40.0M | $54.5M | ||
| Q2 25 | $115.0M | $43.9M | ||
| Q1 25 | $9.0M | $5.1M | ||
| Q4 24 | $-30.0M | $59.3M | ||
| Q3 24 | $80.0M | $73.8M | ||
| Q2 24 | $127.0M | $41.2M | ||
| Q1 24 | $54.0M | $23.8M |
自由现金流ASHCORT
| Q4 25 | $111.0M | $38.4M | ||
| Q3 25 | $6.0M | — | ||
| Q2 25 | $95.0M | $43.9M | ||
| Q1 25 | $-12.0M | $5.0M | ||
| Q4 24 | $-53.0M | $59.2M | ||
| Q3 24 | $42.0M | $72.2M | ||
| Q2 24 | $98.0M | $40.8M | ||
| Q1 24 | $20.0M | — |
自由现金流率ASHCORT
| Q4 25 | 28.8% | 19.0% | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 20.5% | 22.6% | ||
| Q1 25 | -2.5% | 3.2% | ||
| Q4 24 | -13.1% | 32.5% | ||
| Q3 24 | 8.1% | 39.5% | ||
| Q2 24 | 18.0% | 24.9% | ||
| Q1 24 | 3.5% | — |
资本支出强度ASHCORT
| Q4 25 | 3.6% | 0.0% | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 4.3% | 0.0% | ||
| Q1 25 | 4.4% | 0.1% | ||
| Q4 24 | 5.7% | 0.1% | ||
| Q3 24 | 7.3% | 0.9% | ||
| Q2 24 | 5.3% | 0.3% | ||
| Q1 24 | 5.9% | 0.0% |
现金转化率ASHCORT
| Q4 25 | — | 1.58× | ||
| Q3 25 | 1.29× | 2.77× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | 0.29× | 0.25× | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | 4.71× | 1.56× | ||
| Q2 24 | 21.17× | 1.16× | ||
| Q1 24 | 0.45× | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
CORT
暂无分部数据
